Shattuck Labs, Inc. (STTK) Cash Flow Statement

The relationship between net income and operating cash flow is notably consistent, with OCF almost always being a slightly smaller negative number than net income. This indicates that non-cash expenses, primarily stock-based compensation and depreciation, are the main drivers of the difference, but they are not sufficient to create positive cash flow from operations. For a pre-revenue biotech, this pattern is expected, as net losses are driven by R&D and SG&A cash outlays, with the small gap confirming that accrual adjustments are minimal.

The FCF trajectory shows no sign of inflection, with quarterly deficits persisting well above $10 million in most recent periods. This is a direct function of the company's operational structure, where R&D and SG&A spending are fixed cash outlays in the absence of meaningful revenue. The trajectory is deteriorating in the sense that the absolute cash burn remains substantial, and the lack of revenue means there is no natural offset to these expenditures, making the path to positive FCF entirely dependent on external funding or a partnership deal.

The near-zero CapEx profile is consistent with a clinical-stage biotechnology firm that outsources most manufacturing and does not maintain significant fixed assets. This lack of capital intensity means that virtually all operating cash flow is directed toward personnel and research activities. However, this also implies that the company's asset base is intangible and may not support traditional debt financing, increasing reliance on equity markets to fund operations.

The absence of any shareholder returns or material M&A activity confirms that management is conserving cash to extend the operational runway. The single small acquisition appears to be an opportunistic, likely IP-related purchase, not a strategic transformation. This lack of deployment is a necessity, not a choice; any significant cash outflow for non-operational purposes would immediately heighten solvency concerns.